C12N 2740/11011
Alpharetrovirus
Official title: Alpharetrovirus, e.g. avian leucosis virus
C12N2740/11011 (Alpharetrovirus) appears on 104 US grants and 84 published applications in this corpus.
Search patents in C12N- Granted patents
- 104
- Published applications
- 84
- Assignees
- 74
- Inventors
- 193
- Latest grant
- 30 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 2 | 0 |
| 1989 | 5 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 5 | 0 |
| 1997 | 3 | 0 |
| 1998 | 3 | 0 |
| 1999 | 3 | 0 |
| 2000 | 6 | 0 |
| 2001 | 3 | 0 |
| 2002 | 4 | 2 |
| 2003 | 2 | 4 |
| 2004 | 3 | 4 |
| 2005 | 2 | 1 |
| 2006 | 5 | 7 |
| 2007 | 0 | 2 |
| 2008 | 3 | 2 |
| 2009 | 3 | 4 |
| 2010 | 2 | 2 |
| 2011 | 1 | 5 |
| 2012 | 1 | 3 |
| 2013 | 4 | 4 |
| 2014 | 5 | 5 |
| 2015 | 3 | 5 |
| 2016 | 3 | 4 |
| 2017 | 2 | 3 |
| 2018 | 2 | 0 |
| 2019 | 3 | 3 |
| 2020 | 2 | 6 |
| 2021 | 1 | 4 |
| 2022 | 2 | 0 |
| 2023 | 3 | 5 |
| 2024 | 4 | 4 |
| 2025 | 2 | 4 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2740/11022New viral proteins or individual genes, new structural or functional aspects ofIndexing code45
- C12N 2740/11041Use of virus, viral particle or viral elements as a vectorIndexing code42
- C12N 2740/11023Virus like particles [vlp]Indexing code9
- C12N 2740/11051Methods of production or purification of viral materialIndexing code8
- C12N 2740/11034Use of virus or viral component as vaccineIndexing code4
- C12N 2740/11061Methods of inactivation or attenuationIndexing code2
- C12N 2740/11021Viruses as suchIndexing code0
- C12N 2740/11031Uses of virus other than therapeutic or vaccineIndexing code0
All 12 subgroupsShow fewer
Recent patents
- VLP-based monovalent ebola vaccines and methods of making and using same30 Sep 2025US 12,427,190 B2Children's Hospital Medical Center
- VLP-based bivalent Ebola vaccines and methods of making and using same22 Apr 2025US 12,280,100 B2Children's Hospital Medical Center
- Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon30 Jul 2024US 12,049,639 B2The USA, as represented by the Secretary, Dept. of Health and Human Services
- Particle delivery systems7 May 2024US 11,976,277 B2Scribe Therapeutics Inc.
- RNA-based delivery systems with levels of control2 Apr 2024US 11,946,066 B2California Institute of Technology
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Glycoproteins for pseudotyping retroviral vector particles25 Dec 2025US 2025/0388924 A1Medizinische Hochschule Hannover
- Alpharetrovirus-based particles for delivery of rna into cells30 Oct 2025US 2025/0333759 A1Medizinische Hochschule Hannover
- Compositions and methods for modifying eukaryotic cells18 Sep 2025US 2025/0290097 A1Orchard Therapeutics (Europe) Limited
- Compositions, systems, and methods for prime editing29 May 2025US 2025/0171810 A1The Trustees of Columbia University in the City of New York
Most cited
By later US patents
- Transgenic non-human mammals531US 4,736,866 APresident and Fellows of Harvard College · 1988
- Helper cell261US 4,650,764 AWisconsin Alumni Research Foundation · 1987
- Method and means for producing high titer, safe, recombinant lentivirus vectors261US 5,994,136 ACell Genesys, Inc. · 1999
- Composition for introducing nucleic acid complexes into higher eucaryotic cells257US 5,547,932 ABoehringer Ingelheim International GmbH · 1996
- Process for preparing virus disease live vaccines107US 4,071,618 AThe Research Foundation for Microbial Diseases of Osaka University · 1978